TARIS® IS LEVERAGING ITS UNIQUE EXPERTISE IN BLADDER BIOLOGY TO DEVELOP NOVEL TREATMENT OPTIONS FOR BLADDER DISEASES.
TARIS® is advancing programs for the treatment of both muscle invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC). We are developing continuous local therapies for the treatment of bladder cancer using approved oncology agents. We believe that continuous drug exposure to these tumors at relevant drug concentrations has the potential to substantially improve tumor response while still being tolerated locally and mitigating systemic side-effects.
MIBC: TARIS®'s continuous local therapy for MIBC tumors aims to improve patient survival and overall outcomes, and is complementary to both current surgical and systemic pharmacological interventions.
NMIBC: TARIS®'s program for NMIBC aims to improve the pharmacologic management of this disease by:
- Reducing rates of disease recurrence and progression;
- Lowering lifetime treatment costs; and
- Reducing the need for radical cystectomy, a major surgical intervention.
MIBC Collaboration: In December 2017, TARIS and Bristol-Myers Squibb announced a clinical trial collaboration investigating TAR-200 in combination with Opdivo® (nivolumab). The Phase 1b trial will evaluate the combination in patients with MIBC who are scheduled for radical cystectomy.
TARIS® is advancing programs for the treatment of both idiopathic overactive bladder (iOAB) and neurogenic detrusor overactivity (NDO). We are developing a continuous local therapy for the management of OAB using an approved agent. By dosing this drug directly to the bladder for an extended period, we believe that the TARIS® system has the potential to offer improved efficacy while minimizing bothersome systemic side effects seen with oral administration of these types of agents. We believe this has the potential to become a less invasive option for patients unsatisfied with oral treatments, and seeking additional therapy.
Additional Areas of Focus
In addition to our lead programs in bladder cancer and overactive bladder, TARIS® continues to evaluate new products that may address additional areas of unmet need.